Latest Conference Articles

Gurbakhash Kaur, MD, discusses how quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping the role of autologous transplant in multiple myeloma.

A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.

Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

At IMS 2026, mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, while other abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.

David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.

Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.

First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.

The B7-H3–directed antibody-drug conjugate risvutatug rezetecan improved overall survival in the China-based ARTEMIS-008 study of relapsed extensive-stage small cell lung cancer presented at WCLC.

ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.

The phase 2 RESTORE-PV trial is exploring the monoclonal antibody DISC-3405 in polycythemia vera across 2 dosing cohorts.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer community cancer care.

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, and change management through shared implementation strategies.

ASCO 2026 data show ePRO symptom tracking keeps cancer patients on therapy longer, cuts hospitalizations and costs, and may boost survival.

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, improving toxicity control and reducing hospitalizations.

ASCO 2026 real-world data tie GLP-1 drugs to longer cancer survival, but oncology EHRs miss timing and duration—heres why it matters.

Real-world community oncology data link GLP-1 drugs to 34% lower death risk across cancers, prompting calls for prospective trials.

Oral golcadomide with rituximab delivers high responses and manageable safety, enabling outpatient care for relapsed follicular lymphoma.

Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.